Celaid Therapeutics Inc.
R&D Cost of HSC Expansion Platform Technology for Cell and Gene Therapy Companies

Program name

Deep-Tech Startups Support Program

Research theme

R&D Cost of HSC Expansion Platform Technology for Cell and Gene Therapy Companies

Business Plan

To establish an effective and efficient culture and manufacturing platform for human hematopoietic stem cells — a critical bottleneck in the commercial production of gene-modified hematopoietic stem cell therapies and iPSC-derived T/NK cell products — thereby building the foundation for future technology licensing activities to biotech start-ups and global pharmaceutical companies.

Research Outline

This R&D project aims to out-license the platform technology to global customers — including multinational pharmaceutical companies, biotechnology firms, and CDMOs — by achieving the following objectives:

1. Realization of 3D culture for hematopoietic stem cells
2. Establishment of methods for generating and expanding high-quality iPSC-derived hematopoietic stem/progenitor cells
3. Acquisition of R&D data tailored to customer needs

International collaborative technology demonstration

• Download this page（250KB）